

West of Scotland Cancer Network
Haemato-oncology MCN Work Plan 2023/2024

	Actions Required	Lead	Due Date
1.	Continue to engage with the Regional MDT Improvement Programme to optimise operational efficiency and effectiveness of the MDT		
1.1	Work with MDT programme Board and eHealth colleagues to progress development of the MDT system ready for regional implementation, utilising the agreed core dataset for haemato-oncology.	MDT-FIT Project Facilitator	Ongoing
1.2	Agree actions arising from the MDT-FIT QA process and engage with local MDTs to deliver against these.	MCN Clinical Lead MCN&I Manager Local MDT Leads and members	Ongoing
2.	Support the development of a regional guideline on the management of treatment induced premature menopause in patients with blood cancer		
2.1	Review current management of patients across the WoS with treatment induced premature menopause	MCN Clinical Lead MCN&I Manager MCN Clinicians	Jun 23
2.2	Identify lead author and communicate requirements of the guideline development process in accordance with WoSCAN Standard Operating Procedures.	MCN Clinical Lead MCN&I Manager MCN Clinicians	Jul 23
2.3	Develop a guideline for regional implementation.	MCN Clinical Lead MCN&I Manager MCN Clinicians	Sep 23
3.	Continue to rationalise and co-ordinate testing for haematological malignancies in the WoS		
3.1	Develop testing workflows based on current practice for use in the development of a regional lymphoma diagnostic pathway.	MCN&I Manager Molecular Diagnostics Subgroup	Mar 24
3.2	Identify other areas where regional diagnostic testing pathways would be appropriate and produce a phased plan for development.	MCN&I Manager Molecular Diagnostics Subgroup	Mar 24

	Actions Required	Lead	Due Date
4.	Develop and maintain regional/national clinical guidelines to optimise patient care		
4.1	<p>Co-ordinate the development/review of clinical management guidelines and clinical guidance documents in line with WoSCAN SOP.</p> <p>CMGs</p> <ul style="list-style-type: none"> • Acute Lymphoblastic Leukaemia • Acute Myeloid Leukaemia • Polycythaemia Vera • Essential Thrombocythaemia • Myeloma • Hairy Cell Leukaemia • Primary CNS Lymphoma • CLL • CNS Prophylaxis in DLBCL • Marginal Zone Lymphoma • CML • Follicular NHL • Burkitt Lymphoma • DLBCL • Myelofibrosis <p>CGDs</p> <ul style="list-style-type: none"> • Acute Leukaemia Regional Follow-up Guideline • Regional Guideline for Imaging in Myeloma • Lymphoma Regional Follow-up Guideline 	<p>MCN Clinical Lead MCN&I Manager MCN Clinicians</p>	<p>May 23 May 23 May 23 May 23 May 23 May 23 Jun 23 Jun 23 Jul 23 Aug 23 Oct 23 Dec 23 Dec 23 Dec 23</p> <p>Jun 23 Aug 23 Jan 24</p>
5.	Maintain regional service configuration map for Haemato-oncology		
5.1	Update activity.	MCN&I Manager	Jun 23
5.2	Refresh as per any changes in configuration.	MCN&I Manager	Mar 24

	Actions Required	Lead	Due Date
6.	Deliver regional Haemato-oncology education event which facilitates review of clinical audit data, as required, and promotes shared learning of current best practice and innovation		
6.1	Develop a focused programme for the event, addressing relevant key issues.	MCN Clinical Lead MCN&I Manager	Oct 23
6.2	Establish data requirements for the event, and identify any arising from the event. <ul style="list-style-type: none"> • Liaise with Information Team regards audit presentation requirements • Liaise with Information Team if any further audit opportunities identified • Ensure appropriate data sharing agreements issued, completed, agreed and passed to Information Team 	MCN Clinical Lead MCN&I Manager Information Team	Oct 23
6.3	Develop action plans arising from the event and monitor progress of agreed actions. <ul style="list-style-type: none"> • Record actions arising from discussion at event • Develop action plans of same • Issue action plans as appropriate • Monitor progress of actions recorded 	MCN Clinical Lead MCN&I Manager	Mar 24
7.	Use clinical data to drive improvement in quality of care and outcomes		
7.1	Review QPI audit findings to identify variation in practice and highlight exceptions. <ul style="list-style-type: none"> • Performance Summary Returns Assessed • RCOG exception report produced • Governance review and Interrogation of QPI exceptions • Agreement of actions for inclusion in annual audit reports • Input to the production of Annual Audit Report 	MCN Clinical Lead MCN&I Manager Information Manager Information Analyst	May 23 (Lym) Mar 23 (AL)
7.2	Identify requirements for further data analysis to aid understanding of variance, and develop action/improvement plan. <ul style="list-style-type: none"> • Building on results from previous audit, undertake a more in-depth audit of the tissue typing pathway for patients coming to transplant 	MCN Clinical Lead MCN&I Manager MCN Clinical Lead	Mar 24 Dec 23
7.3	Monitor and ensure progress with regional and local board action/improvement plans. <ul style="list-style-type: none"> • Conclusion of actions from QPI Exception Report 	MCN&I Manager Board Clinical Effectiveness Leads	Mar 24
7.4	Contribute to the national Lymphoma QPI formal review process, ensuring appropriate engagement across all specialties.	MCN Clinical Lead MCN Manager	

	Actions Required	Lead	Due Date
	<ul style="list-style-type: none"> Engage with wide MCN for feedback on potential changes to existing QPIs and suggestions for new QPIs Review MCN feedback and consider refinements Engage with Lymphoma Clinical Leads in SCAN and NCA in advance of review meeting regarding any proposed changes 	Advisory Board	Apr 23 May 23 Jun 23
8. Watching brief and development as required on the following work streams			
8.1	Maintain a watching brief on work currently ongoing to establish a Haematological Malignancy Diagnostic Service (HMDS) in the West of Scotland to support the improvement of blood cancer diagnostics	MCN Clinical Lead MCN&I Manager MCN Clinicians	TBC
8.2	Maintain watching brief on the development of a national digital solution for Treatment Summaries, and provide input or support where requested	Designated Clinical Lead MCN&I Manager	TBC
8.3	Maintain watching brief on the roll out of the Regional prehabilitation workstream in line with the actions outlined in the WoSCAN Regional Delivery Plan for Best Preparation for Treatment (Pre-treatment), and provide input or support where requested.	Designated Clinical Lead MCN&I Manager	TBC
8.4	Maintain watching brief on roll out of Regional PROMS workstream in line with the actions outlined in the WoSCAN Regional Delivery Plan for Person Centred Care for All, and provide input or support where requested.	Designated Clinical Lead MCN&I Manager	TBC